Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology.
Even with aggressive therapy, the majority of women with early breast cancer will not achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Investigational agents such as immunotherapy may increase pCR rates, but are also associated with irreversible immune-related toxicities, research shows.
